Table 1.
Imaging Method | Cases/Controls | Outcome | Serum Ft | |
---|---|---|---|---|
Allen et al.64 | MRI (R2′) | 5 vs. 5 | ↓ iron in SN and putamen in RLS patients | N/A |
Earley et al.65 | MRI (R2′) | 22 early, 19 late onset, 39 controls | ↓ iron in SN and putamen in RLS patients | Individuals with serum Ft <18 μg/L were excluded, between group differences not evaluated |
Haba‐Rubio et al.66 | MRI (R2′) | 2 vs. 9 | ↓ iron in SN, red nucleus and putamen in hemochromatosis patients with RLS | N/A |
Astrakas et al.67 | MRI (T2) | 25 vs. 12 | ↓ iron in SNpc and trend toward ↓ iron in caudate and dentate nucleus in patients with RLS | No difference between groups |
Godau et al.69 | MRI (T2) TCS | 6 vs. 19 | Multiregional brain iron deficiency in RLS patients | For RLS 174.8 ± 50.7 ng/mL; N/A for controls |
Knake et al.63 | MRI (T2*) | 12 vs. 12 | No differences in iron deposition between cases and controls in 12 brain regions | 111.9 ± 63.4 vs. 124.7 ± 171.8 ng/mL |
Margariti et al.68 | MRI (T2) | 11 versus 11 | ↑ iron in GP and STN in RLS patients | N/A |
Rizzo et al.70 | MRI (phase imaging) | 15 versus 15 | ↓ iron in SN, thalamus, putamen, and pallidum of RLS patients | 71 ± 45 versus 82 ± 48 ng/mL |
Schmidauer et al.71 | TCS | 20 RLS versus 20 PD versus 20 controls | ↓ iron in SN in RLS patients | For RLS 78.4 ± 16.9 ng/mL; N/A for PD and controls |
Godau et al.72 | TCS | 49 versus 49 | ↓ iron in SN in RLS patients | N/A |
Pedroso et al.73 | TCS | 30 individuals with RLS and either PD or Machado‐Joseph disease | ↓ iron in SN correlates with RLS severity | N/A |
N/A, not available.